2020
Ocular Tuberculosis in Human Immunodeficiency Virus and Systemic Tuberculosis Co-infected Patients
Jain S, Bajgai P, Kaur S, Dogra M, Sharma A, Sharma K, Katoch D, Dogra M, Gupta V, Singh R. Ocular Tuberculosis in Human Immunodeficiency Virus and Systemic Tuberculosis Co-infected Patients. Ocular Immunology And Inflammation 2020, 29: 1002-1006. PMID: 32083986, DOI: 10.1080/09273948.2020.1714059.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusTB co-infected patientsOcular tuberculosisDisseminated TBOcular TBImmunodeficiency virusDiagnosis of disseminated TBTuberculosis co-infected patientsHuman immunodeficiency virus patientsNon-comparative case seriesCo-infected patientsOcular examinationOcular symptomsExtrapulmonary TBCase seriesSystemic examinationClinical findingsEye examPatientsTuberculosisExaminationVirusDiagnosisSymptomsPrevalence
2019
Cytokine profiles of Necator americanus and Plasmodium falciparum co-infected patients in rural Ghana
Amoani B, Adu B, Frempong MT, Sarkodie-Addo T, Nuvor S, Abu EK, Harrison LM, Cappello M, Gyan B, Wilson MD. Cytokine profiles of Necator americanus and Plasmodium falciparum co-infected patients in rural Ghana. Cytokine X 2019, 1: 100014. PMID: 33604551, PMCID: PMC7885886, DOI: 10.1016/j.cytox.2019.100014.Peer-Reviewed Original ResearchCo-infected individualsCytokine profileStool samplesCCL11 levelsMalaria parasitaemiaBlood parasitemia levelsCo-infected patientsIL-10 levelsIL-5 levelsTNF-α levelsCytokines interleukin-5Kato-Katz methodCross-sectional studyHuman immune responseTumor necrosis factorKintampo North MunicipalityPresence of hookwormEffect of hookwormRural GhanaEffector mediatorsHookworm intensityCytokine levelsAlbendazole treatmentSerum levelsCytokine responsesContemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
Maughan A, Sadigh K, Angulo-Diaz V, Mandimika C, Villanueva M, Lim JK, Ogbuagu O. Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients. BMC Infectious Diseases 2019, 19: 378. PMID: 31053098, PMCID: PMC6500032, DOI: 10.1186/s12879-019-3974-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAminoisobutyric AcidsAnti-Retroviral AgentsAntiviral AgentsBenzimidazolesCarbamatesCoinfectionCyclopropanesDrug InteractionsFemaleHepacivirusHepatitis CHeterocyclic Compounds, 4 or More RingsHIV InfectionsHumansLactams, MacrocyclicLeucineLiver CirrhosisMaleMiddle AgedProlinePyrrolidinesQuinoxalinesSofosbuvirSulfonamidesTreatment OutcomeViral LoadConceptsHIV-HCVExclusion criteriaClinical trialsHIV-HCV co-infected patientsNew hepatitis C treatmentsHepatitis C virus infectionCo-infected patientsHIV patient populationC virus infectionGlecaprevir/pibrentasvirSofosbuvir/velpatasvirExcellent cure ratesHIV viral loadMajority of patientsHepatitis C treatmentInjection drug useReal-world populationART regimenHCV agentsCurrent regimensDecompensated cirrhosisViral loadPangenotypic activityCure ratePatient population
2018
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva MS, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2018, 6: 620. PMID: 30344999, PMCID: PMC6171717, DOI: 10.12688/f1000research.11397.2.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infectionPilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugs
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2014
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2012
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntibiotics, AntitubercularCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patientsTreatment outcome, mortality and their predictors among HIV-associated tuberculosis patients
Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, Shamai M, Amiri M, Nikaein S, Mansouri D, Masjedi M, Altice F. Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal Of STD & AIDS 2012, 23: e1-e4. PMID: 23033530, PMCID: PMC3495268, DOI: 10.1258/ijsa.2009.009093.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyTreatment outcomesTB/HIV co-infected patientsHIV co-infected patientsCat II treatmentCo-infected patientsTB-HIV patientsSerum albumin levelIntravenous drug useRisk of deathLower body weightHistory of imprisonmentAntiretroviral therapyLaboratory characteristicsTB treatmentTuberculosis patientsAlbumin levelsHIV transmissionMean ageII treatmentTB centersAlcohol abuseBetter outcomesPatientsBody weight
2011
Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2007
Co-infection with human immunodeficiency virus and tuberculosis in Asia
Vermund SH, Yamamoto N. Co-infection with human immunodeficiency virus and tuberculosis in Asia. Tuberculosis 2007, 87: s18-s25. PMID: 17631414, PMCID: PMC2031213, DOI: 10.1016/j.tube.2007.05.008.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant Mycobacterium tuberculosisDrug-resistant Mycobacterium tuberculosisCo-infected patientsHuman immunodeficiency virusDeath of HIVPublic health workersHIV-tuberculosisHIV seroprevalenceTuberculosis casesImmunodeficiency virusHealth workersTuberculosis accountsPublic health situationMarked riseMycobacterium tuberculosisKey subpopulationsHealth situationTuberculosisResearch prioritiesSalient studiesHigher numberHIVPatientsSeroprevalenceInterdisciplinary collaboration
2006
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet 2006, 368: 1575-1580. PMID: 17084757, DOI: 10.1016/s0140-6736(06)69573-1.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisCo-infected patientsXDR tuberculosisMDR tuberculosisHIV co-infected patientsCulture-confirmed tuberculosisRecent hospital admissionTime of diagnosisSecond-line drugsDrug susceptibility testingCause of deathDate of deathHigh mortality rateAntiretroviral therapyMedian survivalHospital admissionSputum cultureHIV-1PatientsMortality rateHigh mortalityUrgent interventionTreatment programTuberculosisSusceptibility testing
2005
Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans
Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005, 19: s99-s105. PMID: 16251836, DOI: 10.1097/01.aids.0000192077.11067.e5.Peer-Reviewed Original ResearchConceptsHIV/HCV-coHepatitis C virusAlcohol-related complicationsComorbid conditionsHCV-coTreatment optionsHIV monoChart extractionDiagnostic codesMental disordersCo-infected patientsElectronic medical record systemTreatment contraindicationsMedical record systemC virusHigh prevalenceMedical disordersHIVDemographic dataComorbiditiesLogistic regressionPrevalenceModerate agreementRelative prevalenceVeterans
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply